Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
labasiran
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
Labasiran (DV3396) is a GalNAc-conjugated small interfering RNA (siRNA) developed by Novo Nordisk, originally discovered by Dicerna Pharmaceuticals using its proprietary GalXC platform. It is designed to treat non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), by targeting the mRNA of the HSD17B13 (Hydroxysteroid 17-Beta Dehydrogenase 13) gene. Genetic evidence suggests that individuals with loss-of-function mutations in HSD17B13 are protected against the progression of liver diseases, including NASH and cirrhosis. Labasiran mimics this protective effect by silencing the gene in hepatocytes, thereby reducing liver inflammation and preventing the progression of fibrosis. The drug is administered subcutaneously and is currently being evaluated in Phase 2 clinical trials.
- Other names
- labasiranumHSD17B13 RNAiHSD-17B13 RNAiHSD 17B13 RNAi
02
Targets
HSD17B13 (17β-Hydroxysteroid Dehydrogenase Type 13)
Beyond the preview
Go deeper on labasiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on labasiran.